rtog_0825

RTOG 0825

Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Protocol Documents Principal Investigator: Mark R. Gilbert, MD Primary Objective:

To determine whether the addition of bevacizumab to temozolomide and radiation improves efficacy as measured by progression-free and/or overall survival. Patient Population:

Histopathologically confirmed glioblastoma (WHO Grade IV) confirmed by central pathology tissue screening prior to step 2 registration. Tumor tissue that is determined by central pathology tissue screening prior to step 2 registration to be of sufficient size for analysis of MGMT status and determination of molecular profile. The tumor must have a supratentorial component.

  • rtog_0825.txt
  • Last modified: 2018/09/20 08:37
  • by administrador